Browsing Category
Pharma Industry News
4743 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Can final-year OI data rescue Ultragenyx’s $245M pipeline gamble on setrusumab?
Ultragenyx’s setrusumab trial didn’t stop early—but can final data still unlock $245M in milestones and rescue biotech investor confidence?
Can Dr. Reddy’s GLP-1 strategy position it as a key player in the global metabolic drug race?
Explore Dr. Reddy’s GLP‑1 pipeline, patent strategy, and emerging market focus—can the Hyderabad-based pharma firm lead India’s metabolic drug push?
Takeda’s oveporexton Phase 3 trials show broad success in narcolepsy type 1, paving way for 2025 FDA submission
Takeda announces pivotal Phase 3 trial results for oveporexton (TAK-861), showing statistically significant improvements in narcolepsy type 1 symptoms. Regulatory filings planned.
Can rilparencel’s eGFR gains in Group 1 justify accelerated FDA approval for ProKidney in 2025?
ProKidney’s rilparencel showed a 78% improvement in eGFR slope—can this surrogate endpoint clear the way for FDA fast-track approval in 2025?
Crohn’s disease market grows to $13.8bn—can NeuroScientific’s stem cell pivot capture real value?
Explore how NeuroScientific’s StemSmart therapy targets a $13.8B Crohn’s market with MSC innovation for hard-to-treat patient segments.
Median Technologies secures €37.5m EIB funding to advance eyonis AI cancer diagnostics and US launch
Median Technologies secures €37.5M from the European Investment Bank to accelerate AI-driven eyonis® cancer screening software commercialization in the US and EU.
Can Amplia’s 31% response rate help narmafotinib break into FDA fast-track territory?
Can Amplia's narmafotinib gain FDA fast-track after 31% pancreatic cancer response rate? Explore its trial results, U.S. plans, and Project Optimus path.
Verastem Oncology’s avutometinib plus defactinib trial in LGSOC published in JCO with robust clinical responses
Verastem Oncology published pivotal Phase 2 RAMP 201 trial results in JCO, showing strong response rates for avutometinib plus defactinib in recurrent LGSOC.
Indegene (NSE: INDGN) unveils AI-powered NEXT platform to automate medical writing workflows
Find out how Indegene is transforming medical writing with its new AI-powered NEXT platform for life sciences documentation workflows.
NeuroScientific Biopharmaceuticals stock watch: Can StemSmart turn NSB into a clinical-stage contender?
Is NeuroScientific Biopharmaceuticals the next stem cell breakout? Explore NSB’s clinical pivot, share surge, and StemSmart’s investor impact now.